癌症肿瘤分析市场规模、份额和成长分析（按癌症类型、生物标记类型、技术、方法、应用和地区划分）－2026-2033年产业预测

全球癌症肿瘤分析市场规模预计在 2024 年达到 134.4 亿美元，从 2025 年的 149.3 亿美元增长到 2033 年的 346.6 亿美元，在预测期（2026-2033 年）内复合年增长率为 11.1%。

全球癌症肿瘤分析市场正经历强劲增长，这主要得益于癌症发病率的上升以及对生物标记在检测和治疗中日益增长的依赖。此外，研究经费的增加、技术的创新以及向个人化医疗和照护现场诊断的转变也进一步推动了这一增长，为行业相关人员创造了巨大的机会。儘管新冠疫情暂时影响了癌症检测和诊断，但长期前景仍然乐观。市场中的关键细分领域——基因组学、蛋白质组学、表观遗传学和代谢体学——预计将持续成长，其中基因组学预计将呈现最高的成长率。该技术在识别促进癌细胞增殖的基因突变方面发挥关键作用，从而促进先进的肿瘤分析，有助于指导治疗策略并改善患者预后。

全球癌症肿瘤分析市场驱动因素

全球癌症肿瘤分析市场的成长主要受全球癌症发生率上升的驱动。癌症病例激增与多种因素相关，例如人口老化和成长，以及各种癌症风险因子盛行率的变化。癌症本身的复杂性，受多种因素影响，进一步加剧了这一局面。随着越来越多的人被诊断出患有各种类型的癌症，对综合肿瘤分析服务的需求正在加速增长，这凸显了开发先进诊断工具以应对癌症检测和治疗复杂性的必要性。

阻碍因素

样本采集和保存方面的技术难题对全球癌症肿瘤谱分析市场的扩张构成重大障碍。医疗保健领域个人化医疗的快速发展已经彻底改变了多种疾病的识别、分类和治疗方式，使其成为主流临床实践的重要组成部分。儘管肿瘤学领域取得了显着进展，但这些进展固有的风险和併发症可能会阻碍市场整体成长。解决这些技术难题对于充分发挥肿瘤谱分析的潜力、改善癌症治疗的患者照护和疗效至关重要。

全球癌症肿瘤分析市场趋势

全球癌症肿瘤分析市场正经历显着成长，这主要得益于体学数据的整合和液态生物检体技术的进步。个人化医疗的兴起也推动了这一趋势，它正在革新癌症的识别、分类和治疗方式。随着个人化医疗方法在临床实践中逐渐成为主流，在各种肿瘤学应用中也得到了越来越广泛的应用。这种转变不仅提高了诊断的准确性，也改善了治疗效果，从而促进了更有效、更具针对性的癌症治疗生态系统的建构。因此，预计在革新全球肿瘤学实践的技术创新驱动下，该市场将迎来强劲成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球癌症肿瘤分析市场规模（依癌症类型划分）及复合年增长率（2026-2033 年）

• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌
• 黑色素瘤
• 其他癌症

全球癌症肿瘤分析市场规模（按生物标记类型和复合年增长率划分）（2026-2033 年）

• 基因生物标誌物
• 蛋白质生物标记

全球癌症肿瘤分析市场规模（依技术及复合年增长率划分）（2026-2033 年）

• 免疫检测
• 次世代定序
• 聚合酵素链锁反应
• 质谱分析
• 原位杂合反应
• 微阵列
• 其他的

全球癌症肿瘤分析市场规模（依技术及复合年增长率划分）（2026-2033 年）

• 基因组学
• 蛋白质体学
• 代谢体学
• 表观遗传学

全球癌症肿瘤分析市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 研究
• 生物标记发现
• 个人化医疗
• 临床应用
• 诊断
• 预后诊断
• 筛检
• 治疗和监测

全球癌症肿瘤分析市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Illumina, Inc.（USA）
• QIAGEN NV（Netherlands）
• NeoGenomics, Inc.（USA）
• Thermo Fisher Scientific（USA）
• Roche Diagnostics（Switzerland）
• Guardant Health, Inc.（USA）
• Foundation Medicine, Inc.（USA）
• Sysmex Corporation（Japan）
• Becton, Dickinson and Company（BD）（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（USA）
• Johnson & Johnson（USA）
• Danaher Corporation（USA）
• Abbott Laboratories（USA）

结论与建议

Global Cancer Tumor Profiling Market size was valued at USD 13.44 Billion in 2024 and is poised to grow from USD 14.93 Billion in 2025 to USD 34.66 Billion by 2033, growing at a CAGR of 11.1% during the forecast period (2026-2033).

The global market for cancer tumor profiling is experiencing robust growth, driven by the rising incidence of cancer and the increasing reliance on biomarkers for detection and treatment. This expansion is further fueled by heightened research funding, technological innovations, and the shift towards personalized medicine and point-of-care diagnostics, creating significant opportunities for industry players. Although the COVID-19 pandemic temporarily impacted cancer testing and diagnosis, the long-term outlook remains optimistic. Key segments within the market-genomics, proteomics, epigenetics, and metabolomics-are anticipated to flourish, with genomics expected to showcase the highest growth rate. This technique plays a critical role in identifying gene mutations that allow cancer cells to thrive, facilitating advanced tumor profiling to inform treatment strategies and improve patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Tumor Profiling market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Tumor Profiling Market Segments Analysis

Global Cancer Tumor Profiling Market is segmented by Cancer type, Biomarker type, Technology, Technique, Application and region. Based on Cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer. Based on Biomarker type, the market is segmented into Genomic Biomarker and Protein Biomarker. Based on Technology, the market is segmented into Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays and Others. Based on Technique, the market is segmented into Genomics, Proteomics, Metabolomics and Epigenetics. Based on Application, the market is segmented into Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening and Treatment and Monitoring. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Tumor Profiling Market

The global cancer tumor profiling market is significantly driven by the rising incidence of cancer worldwide. This surge in cancer cases can be linked to multiple factors, including an aging population and demographic growth, alongside shifts in the prevalence of various cancer risk factors. The intricate nature of cancer, influenced by a diverse array of causes, further exacerbates the situation. As more individuals are diagnosed with different forms of the disease, the demand for comprehensive tumor profiling services is accelerating, highlighting the essential need for advanced diagnostic tools that cater to the complexities of cancer detection and management.

Restraints in the Global Cancer Tumor Profiling Market

Challenges associated with technical issues in the collection and storage of samples pose significant obstacles to the expansion of the global cancer tumor profiling market. As personalized medicine rapidly evolves within healthcare, it transforms the identification, classification, and treatment of various diseases, making it an integral part of mainstream clinical practice. While advancements in oncology are notable, the inherent risks and complications related to these advancements can impede overall market growth. Addressing these technical constraints is critical for harnessing the full potential of tumor profiling to enhance patient care and outcomes in cancer treatment.

Market Trends of the Global Cancer Tumor Profiling Market

The Global Cancer Tumor Profiling market is experiencing significant growth driven by the integration of omics data and advancements in liquid biopsy technologies. This trend is underpinned by the rise of personalized medicine, which is revolutionizing how cancers are identified, classified, and treated. As personalized approaches become mainstream in clinical practice, they are increasingly being utilized across a range of oncological applications. This shift not only enhances diagnostic accuracy but also improves treatment outcomes, leading to a more effective and targeted cancer care ecosystem. Consequently, the market is poised for robust expansion as innovations reshape oncology practices worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cancer Tumor Profiling Market Size by Cancer type & CAGR (2026-2033)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancer

Global Cancer Tumor Profiling Market Size by Biomarker type & CAGR (2026-2033)

• Market Overview
• Genomic Biomarker
• Protein Biomarker

Global Cancer Tumor Profiling Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Immunoassays
• Next-Generation Sequencing
• Polymerase Chain Reaction
• Mass Spectrometry
• In-Situ Hybridization
• Microarrays
• Others

Global Cancer Tumor Profiling Market Size by Technique & CAGR (2026-2033)

• Market Overview
• Genomics
• Proteomics
• Metabolomics
• Epigenetics

Global Cancer Tumor Profiling Market Size by Application & CAGR (2026-2033)

• Market Overview
• Research
• Biomarker Discovery
• Personalized Medicine
• Clinical Application
• Diagnostics
• Prognostics
• Screening
• Treatment and Monitoring

Global Cancer Tumor Profiling Market Size & CAGR (2026-2033)

• North America (Cancer type, Biomarker type, Technology, Technique, Application)
  • US
  • Canada
• Europe (Cancer type, Biomarker type, Technology, Technique, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer type, Biomarker type, Technology, Technique, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer type, Biomarker type, Technology, Technique, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer type, Biomarker type, Technology, Technique, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations